From here is the main content.


Partnering To Our Future Business Partners

Nihon Pharmaceutical Co., Ltd, as a member of the Takeda Pharmaceutical Group, which is the leading pharmaceutical company group in Japan, continues to grow as a unique company specializing in manufacturing, developing and marketing “plasma fractionation products” as well as in a basic and niche fields including of “gastrointestinal medications” and “disinfectants” etc.


We are looking for an opportunity to establish business alliances with companies that are considering exporting own products into the Japanese market or licensing proprietary technologies or drug candidates in order to deliver innovative new drugs to patients as early as possible through the strong sales network of Takeda Pharmaceutical.


TK21 is discovered by Nihon Pharmaceutical Research Laboratories for the treatment of Myasthenia Gravis with innovative mechanisms of action, which is available for out-licensing.

out-licensing available
Compound CodeProduct SummaryTarget IndicationDevelopment StagePatent No.Original Article
TK21Download PDFMyasthenia GravisPre-ClinicalPCT/JP2012/058912Download PDF

If you are interested in either in- or out-licensing alliance with us, please contact the following email address and let us know your proposal.